Lymphoma is the most common lymphoproliferative disorder, and the clinical course largely depends on its indolent or aggressive nature. The treatment regimen for aggressive, high-grade lymphoma often involves cytotoxic therapies, whereas indolent lymphomas can be controlled with minimal cytotoxic therapies with longer remission periods. Therefore, the diagnosis of the correct type of lymphoma is of great importance in optimal disease management. The recent advancement in preclinical research has led to a better understanding of the molecular pathogenesis of lymphoma, including the pathways involved in disease development and progression .
Over the years, several agents (such as chemotherapeutic agents , monoclonal antibodies , and CAR T cells ) have been clinically evaluated for their role in inhibiting the pathway components responsible for causing lymphomas. In this video, Dr. Bharat…
